ArticleCell cycle (Georgetown, Tex.)2013
Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.
Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.Arthritis research & therapy · 2018Trial
- Gut microbiota and epigenetic inheritance: implications for the development of IBD.Gut microbes · 2025Review
- Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.Frontiers in oncology · 2023Review
- Endogenous drivers of altered immune cell metabolism.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- The change of plasma metabolic profile and gut microbiome dysbiosis in patients with rheumatoid arthritis.Frontiers in microbiology · 2022Article
- Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies.International journal of molecular sciences · 2021Article
- Control of T Cell Metabolism by Cytokines and Hormones.Frontiers in immunology · 2021Review
- Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.Arthritis research & therapy · 2018Review
- [Immunometabolism and inflammation : "The cell is what it eats"].Zeitschrift fur Rheumatologie · 2017Article
- Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury.Journal of neurotrauma · 2017Article
- [Biomarkers for prognosis of response to anti-TNF therapy of rheumatoid arthritis: Where do we stand?].Zeitschrift fur Rheumatologie · 2015Review
- The interplay between inflammation and metabolism in rheumatoid arthritis.Cell death & disease · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
Abstract
The autoimmune process in rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases to respond to external stimuli such as cytokines, immune complexes, and antigens. CD4+ T cells comprise a large proportion of the inflammatory cells that invade the synovial tissue and may therefore be a cell type of pathogenic importance. Both methotrexate and infliximab are effective in the treatment of inflammatory arthritis; however, the biological effects triggered by these treatments and the biochemical mechanisms underlining the cell response are still not fully understood. Thus, in this study the global metabolic changes associated with methotrexate or infliximab treatment of isolated human CD4+ T cells were examined using gas chromatography/mass spectrometry or liquid chromatography/mass spectrometry. In total 148 metabolites involved in selective pathways were found to be significantly altered. Overall, the changes observed are likely to reflect the effort of CD4+ cells to increase the production of cellular reducing power to offset the cellular stress exerted by treatment. Importantly, analysis of the global metabolic changes associated with MTX or infliximab treatment of isolated human CD4+ T cells suggested that the toxicity associated with these agents is minimal when used at clinically relevant concentrations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.